Feb 10, 2012
South Carolina adopts positive coverage of Aerocrine’s FeNO testing in Medicaid program
SOLNA, Sweden - 9 February, 2012 - Aerocrine AB (OMX Nordic Exchange: AERO) today announced that South Carolina’s Medicaid program now provides reimbursement of FeNO testing, bringing the total to 31 states including the District of Columbia
Jan 17, 2012
Aerocrine appoints pulmonologist Paul Dorinsky, M.D., as medical director, North America
SOLNA, Sweden – 17 January, 2012 – Aerocrine AB (OMX Nordic Exchange: AERO) today announced that they have strengthened their medical team by adding former Teva R&D VP, Dr. Paul Dorinsky. Paul joins Aerocrine as medical director, North America.
Jan 12, 2012
Aerocrine reaches multiple milestones in Asia, receives market approval in South Korea and Taiwan
SOLNA – 12 January 2012 – Aerocrine AB (OMX Nordic Exchange: AERO) announced that it’s product, NIOX MINO®, has received market approvals on the South Korean and Taiwanese markets. An approval is an important step towards receiving reimbursement for inflammation monitoring with the help of FeNO in asthma management.
Jan 11, 2012
Mississippi’s Medicaid program adds coverage for Aerocrine’s FeNO testing in asthma management following a new ATS guideline
SOLNA, Sweden – 11 January, 2012 – Aerocrine AB (OMX Nordic Exchange: AERO) today announced that Mississippi’s Medicaid program adds FeNO reimbursement coverage, making 29 states plus the District of Columbia covering this cost-effective test for managing asthma.
Dez 5, 2011
Aerocrine’s FeNO technology is standard practice in NHANES data by the CDC to define airway inflammation in US population
SOLNA, Sweden – 5 December 2011 – Aerocrine announced that the Center for Disease Control for Health Statistics measured FeNO as a standard practice in examining the components on respiratory health, using the NIOX MINO device.
Nov 17, 2011
Resolutions at Aerocrine’s Extraordinary General Meeting
An Extraordinary General Meeting (EGM) was held in Aerocrine AB (NASDAQ OMX Stockholm: AERO) on 16 November 2011 in Stockholm. The EGM resolved to approve the proposal by the Board of Directors on the implementation of a long-term incentive program (LIP 2011) and the issuance and approval of transfer of warrants. Thomas Eklund was elected new member of the Board.
Nov 2, 2011
Interim Report January - September 2011
New positive ATS (US) guideline recommends measuring airway inflammation in asthma management. Board appoints new CEO.
Okt 17, 2011
NOTICE OF EXTRAORDINARY GENERAL MEETING
An Extraordinary General Meeting (“EGM”) inAerocrineAB is held on Wednesday 16 November 2011 at 5.00 p.m. CET at the offices of Mannheimer Swartling Advokatbyrå, Norrlandsgatan 21 inStockholm.
Okt 17, 2011
The Board of Aerocrine proposes long-term incentive program
The Board of Directors of Aerocrine AB (NASDAQ OMX Stockholm: AERO) proposes that the shareholders at an Extraordinary General Meeting on 16 November 2011 resolves to implement a long-term incentive program for senior executives as well as other employees and key persons (“LIP 2011”). LIP 2011 includes employee stock options and hedging measures created through the issuance and approval of transfer of warrants. The proposed program is, among other things, part of Aerocrine’s strategy to build and strengthen the company’s U.S. operations and commercial organization.
Sep 13, 2011
Aerocrine AB announces the appointment of Scott Myers to the position of President and Chief Executive Officer
SOLNA, Sweden – 13 September 2011 – Aerocrine AB (OMX Nordic Exchange: AERO) today announced that Scott Myers has been appointed as President and CEO of Aerocrine AB, effective as of today. This appointment is part of the company’s strategy to focus on the reimbursement and commercialization of its products in the U.S. and other key markets. Scott succeeds Paul de Potocki who has successfully led the development of Aerocrine since 2007.
Sep 2, 2011
New ATS guideline recommends measuring airway inflammation in asthma management – a major breakthrough for Aerocrine
SOLNA, Sweden – 2 September 2011 – Aerocrine AB (OMX Nordic Exchange: AERO) today announced that the American Thoracic Society has released an official clinical practice guideline that provides strong recommendations to measure FENO in patients with asthma. FENO is a point-of-care analytical method for trending and management of airway inflammation which has been pioneered by Aerocrine. Asthma is one of the world’s most widespread diseases and affects more than 300 million people, many of whom are children. Every day, 11 people in the U.S. die from asthma.
Sep 1, 2011
Clarifying information regarding trading stop in Aerocrine AB (publ)
SOLNA, Sweden – September 1 2011 – Aerocrine AB (OMX Nordic Exchange: AERO) today announced that trading in the Company's shares was halted in response to speculation regarding the publication of U.S. guidelines regarding the Company's method.
Aug 31, 2011
Change in number of shares and votes in Aerocrine
Aug 15, 2011
Aerocrine appoints Morten Gunvad as VP Commercial Operations Europe and Asia
SOLNA, Sweden – 15 August 2011 – Aerocrine AB today announced the appointment of Morten Gunvad as Vice President Commercial Operations Europe and Asia. Morten will lead the company’s overall sales and marketing operations outside North America to accelerate sales both in Aerocrine’s direct and distributor markets.
Aug 12, 2011
Major US Allergy and Asthma Group Practice Adopts Aerocrine’s Technology
SOLNA, Sweden – 12 August 2011 – Aerocrine AB today announced that Allergy & Asthma Specialists, P.C. has adopted Aerocrine’s FENO technology for airway inflammation measurement as part of its clinical standardization on a system-wide basis. Allergy & Asthma Specialists, P.C. is the largest group practice in the Philadelphia region specializing in allergic disease, asthma and immunology. Allergists use FENO to diagnose eosinophilic airway inflammation in patients with non-specific respiratory symptoms, to predict patient response to corticosteroid therapy, as well as to optimize dosing and assess adherence to anti-inflammatory therapy.
Jul 22, 2011
Interim Report January - June 2011
Sales for routine clinical use in the US continue to show a positive trend. Aerocrine secured the company's largest single order to date, valued at SEK 5.5 million.
Jul 7, 2011
Aerocrine provides update on its patent infringement suit against Medisoft
SOLNA, Sweden – 7 July 2011 – Aerocrine AB today announced a negative decision by the Munich Court regarding the validity of one German Aerocrine patent. This decision does not influence Medisoft’s obligation to respect the existing three courts decisions in Germany.
Jun 30, 2011
Change in number of shares and votes in Aerocrine
Mai 6, 2011
Report from the 2011 Annual General Meeting in Aerocrine AB
The Annual General Meeting in Aerocrine was held on Thursday, May 5, 2011, in Stockholm
Mai 5, 2011
Delårsrapport januari – mars 2011
Fortsatt god försäljningstillväxt i USA för NIOX MINO. Aerocrine vinner patenttvist mot Medisoft. Aerocrine förvärvar tillgångar i FILT GmbH och häver stämningsprocess.
Mai 5, 2011
Interim Report January – March 2011
Continued good growth in sales of NIOX MINO in the US. Aerocrine wins patent dispute against Medisoft. Aerocrine acquires assets in FILT GmbH and withdraws lawsuit.
Apr 29, 2011
Change in number of shares and votes in Aerocrine
Apr 5, 2011
Notice of Annual General Meeting in Aerocrine AB
The Annual General Meeting in Aerocrine AB (publ) is held on Thursday May 5, 2011, 5.00 p.m. CET at the offices of Mannheimer Swartling Advokatbyrå, Norrlandsgatan 21 in Stockholm.
Mrz 29, 2011
Aerocrine appoints Dr. Kathleen Rickard as Chief Medical Officer
SOLNA, Sweden – 29 March 2011 – Aerocrine AB today announced the appointment of Dr. Kathleen Rickard as Chief Medical Officer of the company. Dr. Rickard will be Aerocrine’s primary voice to the global medical community and will speak to critical issues related to airway inflammation monitoring and improved treatment of asthma.
Mrz 18, 2011
Aerocrine acquires FENO assets from FILT and enters into R&D collaboration
SOLNA, Sweden – 18 March 2011 – Aerocrine AB today announced the acquisition of key assets related to the measurement of FENO from German company FILT Lungen & Thoraxdiagnostik GmbH. FILT and Aerocrine will collaborate to develop new applications for airway inflammation monitoring and FILT will cease further commercialization of the NO VARIO® product.
Mrz 16, 2011
Aerocrine and EMR Leader Meditab form Strategic Alliance for Allergy Offices
SOLNA, Sweden – 16 March 2011 – Aerocrine AB (OMX Nordic Exchange: AERO) today announced the launch of a strategic alliance with Meditab Software Inc. at the American Association of Allergy, Asthma and Immunology annual meeting in San Francisco on March 19-21.
Feb 25, 2011
Aerocrine prevails in patent infringement suit against Medisoft
SOLNA, Sweden – 25 February 2011 – Aerocrine AB today announced the positive outcome of its patent proceedings against Medisoft P.A.E. at the Court of Appeal of Dusseldorf and the Federal Patent Court of Munich.
Feb 24, 2011
Year‑end report 2010
Favourable sales growth in the US for NIOX MINO. Total capital of SEK 268 million raised in 2010
Jan 31, 2011
Change in number of shares and votes in Aerocrine
Nov 30, 2010
Change in number of shares and votes in Aerocrine
Okt 29, 2010
Change in number of shares and votes in Aerocrine
Okt 22, 2010
Aerocrine AB:s extraordinary general meeting 2010
An extraordinary general meeting was held in Aerocrine AB (publ) on Thursday 21 October 2010 in Solna
Okt 20, 2010
Aerocrine completes issuance of shares and convertible bond raising a total of SEK 361 million
SOLNA, Sweden – 20 October 2010 – Aerocrine AB (OMX Nordic Exchange: AERO B) today announces the results of the Company’s rights issue. The rights issue increases Aerocrine’s equity by a total SEK 136.1 million. Previously, Aerocrine announced a combined placement of equity and the issuance of convertible notes to Novo A/S raising a total of SEK 225 million. Overall, the Company’s financial position has been strengthened by approximately SEK 361 million.
Okt 5, 2010
Notice of Extraordinary General Meeting in Aerocrine AB
The shareholders of Aerocrine AB (publ) are hereby invited to attend the Extraordinary General Meeting to be held at 4.00 p.m. on Thursday 21 October 2010 at Sundbybergsvägen 9 in Solna.
Sep 22, 2010
Aerocrine Publishes New Issue Prospectus
SOLNA, Sweden – 22 September 2010 - Aerocrine AB (OMX Nordic Exchange: AERO B) today announces the publication of the prospectus for the Company´s rights issue of approximately SEK 155.5 million and the directed issue of new shares and convertible bonds of SEK 225 million to Novo A/S. The prospectus, available in Swedish language only, has been approved by and registered with the Swedish Financial Supervisory Authority (Finansinspektionen).
Sep 16, 2010
Aerocrine Strengthens Financial and Strategic Position by Placement of New Shares and Convertible Bonds. Novo A/S Becomes a Major Shareholder Alongsi
SOLNA, Sweden – 16 September 2010 - Aerocrine AB (OMX Nordic Exchange: AERO B) today announces that on 15 September 2010 the Board, by virtue of authorization by the shareholders’ meeting, decided to carry out a SEK 225 million directed issue of new shares and convertible bonds to Denmark-based Novo A/S, as well as a SEK 155.5 million new share issue with preferential rights to existing shareholders. The issue price and the conversion price of the convertible bonds are set at 13 and 41 per cent premium, respectively, to the closing share price on 15 September, 2010. The proceeds from the issue of new shares and convertible bonds will strengthen Aerocrine’s financial position and enable the company to drive the commercialization of its products.
Mai 19, 2010
Aerocrine acquires all assets of U.S. competitor and ends litigation
SOLNA, Sweden – 19 May 2010 – Aerocrine AB today announced that it has acquired all business assets and intellectual property assets from the bankruptcy estate of Apieron Inc. As a result, Apieron’s litigation against Aerocrine in the U.S. and Germany will be terminated and dismissed. Aerocrine’s patent infringement claims in the U.S. against Apieron’s estate will not be dismissed, however.
Mai 5, 2010
Aerocrine provides IP update
SOLNA, Sweden – 5 May 2010 – Aerocrine AB today announced that it has received a written decision from the District Court of Mannheim that Aerocrine infringes the German counterpart of a U.S. patent that Apieron Inc. purchased in 2004. Since Apieron has filed for bankruptcy and is in liquidation, the decision has no current impact on Aerocrine’s operations.
Apr 7, 2010
Aerocrine provides update on its first quarter sales
SOLNA, Sweden – 7 April 2010 – Aerocrine AB today announced that its first quarter sales development has been below expectations. Revenues are estimated to reach approximately 18 MSEK compared to 26,9 MSEK previous year.
Apr 7, 2010
Aerocrine provides update on its legal action against Apieron
SOLNA, Sweden – 7 April 2010 – Aerocrine AB today announced that its patent infringement cases in the U.S. and Europe against Apieron Inc., Menlo Park, USA will be stayed as a result of Apieron filing for Chapter 7 bankruptcy.
Jan 13, 2010
US Expert Panel recommends the use of Fractional Exhaled Nitric Oxide (FENO) in the diagnosis and management of Asthma.
SOLNA, Sweden – 13 January 2010 – Aerocrine AB (OMX Nordic Exchange: AERO) today announced that a group of prominent clinicians and researchers, all leaders in the field of asthma in the US, has issued a consensus paper recommending that inflammation monitoring using exhaled nitric oxide should be part of the routine clinical management of asthma in conjunction with other conventional methods.
The points of clinical consensus were arrived at during a closed meeting held at National Jewish Health in Denver, Colorado.
Nov 4, 2009
Aerocrine and Panasonic Shikoku Electronics enter into asthma partnership
SOLNA, Sweden – 4 November 2009 – Aerocrine AB (OMX Nordic Exchange: AERO) today announced that Aerocrine and Panasonic Shikoku Electronics, CO., LTD (PSEC) have entered into a long-term agreement to develop, manufacture and market new generation products for airway inflammation monitoring using exhaled nitric oxide.
Sep 24, 2009
Aerocrine wins patent infringement suit against Medisoft in Germany
SOLNA, Sweden – 24 September 2009 – Aerocrine AB today announced the positive outcome of its complaint against Medisoft P.A.E. filed at the District Court of Dusseldorf, Germany.
Sep 3, 2009
Canada Approves NIOX MINO for Asthma Monitoring
SOLNA, Sweden – 3 September 2009 – Aerocrine AB today announced that Health Canada’s Therapeutic Products Directorate has approved Aerocrine’s NIOX MINO® technology for use in treating asthma. Canada’s National Health Service may now begin using the NIOX MINO, a medical device that provides a measure of the degree of inflammation in the airways in a single breath.
Aug 21, 2009
Major insurance company covers Aerocrine’s method for asthma control: Calls eNO measurement “Medically Necessary”
SOLNA, Sweden – 21 August 2009 – CareFirst BlueCross BlueShield, the largest health care insurer in the Mid-Atlantic region of the USA, has adopted a policy stating that measurement of exhaled nitric oxide (eNO) is considered medically necessary in the management of asthma patients.
Aug 19, 2009
Aerocrine provides update on its legal action against Apieron
SOLNA, Sweden – 19 August 2009 – Aerocrine AB today announced that the United States District Court has accepted Aerocrine’s motion for leave to add a third patent to its October 2008 patent infringement complaint against Apieron, Inc. Menlow Park, USA.
Mrz 9, 2009
Swiss physicians to be reimbursed per NIOX MINO® test
SOLNA, Sweden—9 March 2009—Aerocrine AB (OMX Nordic Exchange: AERO) announced today that reimbursement for the routine measurement of airway inflammation has been introduced in the Swiss healthcare system.
Feb 12, 2009
Treating asthma with NIOX MINO® offers cost savings for the UK healthcare system
SOLNA, Sweden, 12 February 2009 - Aerocrine AB (OMX Nordic Exchange: AERO) has reported the recent publication of a UK study evaluating the effect of routine inflammation measurement in asthma.
Nov 12, 2008
Publication of prospectus with respect to Aerocrine´s new share issue 2008
Jun 27, 2008
China opens up to Aerocrine’s asthma test
SOLNA, Sweden, 27 June 2008—Aerocrine AB announced today that its handheld airway inflammation monitor, NIOX MINO®, has been registered for marketing and sale in China.
Aerocrine’s method of measuring airway inflammation, using exhaled nitric oxide (NO) tests, has also been incorporated into China’s national guidelines for asthma management. Tests for airway inflammation have received a reimbursement code.
Apr 8, 2008
Airway inflammation measurement receives reimbursement in Czech Republic
SOLNA, Sweden – 8 April, 2008 – Aerocrine AB (OMX Nordic Exchange: AERO) today announced that a new reimbursement code has been issued for the exhaled NO tests in the Czech healthcare system.
Mrz 20, 2008
Aerocrine files patent infringement suit against Medisoft in Germany
SOLNA, Sweden – 20 March 2008 – Aerocrine AB (OMX Nordic Exchange: AERO) today announced the filing with the District Court of Dusseldorf of a Complaint and Motion to prevent Medisoft, P.A.E from marketing and selling its exhaled Nitric Oxide (NO) analyser in Germany. The claim seeks both an injunction and damages.
Mrz 4, 2008
FDA Grants Market Clearance to Aerocrine Inc.’s NIOX MINO®: a New Hand-Held Device to Measure Airway Inflammation in Asthma
NIOX MINO® Set to Dramatically Improve Airway Inflammatory Disease Management through Personalized Inflammation Control.
NEW PROVIDENCE, N.J., March 4, 2008 – Aerocrine, Inc. today announced that NIOX MINO, a hand-held point-of-care device for the measurement of airway inflammation, has been 510(k) cleared by the U.S. Food and Drug Administration (FDA). Physicians in the U.S. now have a highly accurate, non-invasive and convenient technology that is appropriate for use in a doctor’s office, ultimately helping them improve how they treat asthma patients.
Feb 26, 2008
Financial statement 2007
Record sales in fourth quarter
Feb 11, 2008
Aerocrine enters distribution agreement with Chest in Japan
SOLNA – February 11, 2008 – Aerocrine AB (OMX Nordic Exchange: AERO) announces that the company has entered into a distribution agreement with Chest M.I. Inc. Chest will market and sell NIOX MINO® in Japan.
Feb 7, 2008
Aerocrine appoints new President of Aerocrine Inc.
SOLNA, Sweden – 7 February, 2008 – Aerocrine AB (OMX Nordic Exchange: AERO) today announced the appointment of Chip Neff to the position of President of Aerocrine’s US subsidiary Aerocrine Inc., effective from 25 February 2008. Chip Neff will succeed Trevor Bourke, who has led the development of Aerocrine Inc since 2002. Trevor Bourke will remain at Aerocrine Inc during the transition, prior to taking up a new role in Europe.
Jan 14, 2008
Cost savings in asthma management when using NIOX MINO® First health economic study published
SOLNA – 14 January, 2008 – Aerocrine AB (OMX Nordic Exchange: AERO) reports that the first heath economic study evaluating the effect of introducing measurements of exhaled NO in asthma management has been published.
Jan 9, 2008
Aerocrine strengthens its patent portfolio
SOLNA – 9 January 2008 – Aerocrine AB (OMX Nordic Exchange: AERO) announces that the company has strengthened its patent portfolio by both acquiring a strategically important patent and patenting its own discoveries.
Dez 20, 2007
Aerocrine enters distribution agreement with Phadia in France
SOLNA – 20 December, 2007 – Aerocrine AB (OMX Nordic Exchange: AERO) announces that the company has entered into a distribution agreement with Phadia France.
Dez 7, 2007
NIOX® approved in China. Aerocrine expands its distribution agreement to include NIOX MINO®.
SOLNA – 7 December 2007 – Aerocrine AB (OMX Nordic Exchange: AERO) announces that the company’s NIOX product has been approved by SFDA, the Chinese registration authority. Aerocrine has also entered into a distribution agreement with Bioson Inc. that includes sales of both NIOX and NIOX MINO in China.
Okt 15, 2007
Aerocrine enters collaboration for improved treatment of asthma and intestinal diseases
SOLNA – 15 October, 2007 – Aerocrine AB (OMX Nordic Exchange: AERO) announces that it has become a partner in a program for the development of diagnostic methods for allergies, asthma and food hypersensitivity.
Okt 2, 2007
Aerocrine submits 510(k) filing for NIOX MINO® in the U.S.
SOLNA – October 2, 2007 – Aerocrine AB (OMX Nordic Exchange: AERO) announced that it has submitted a 510(k) application for marketing clearance to the U.S. Food & Drug Administration (FDA) for its NIOX MINO® device.
Sep 17, 2007
Aerocrine appoints Vice President Global Sales
SOLNA – 17 September, 2007 – Aerocrine appoints new senior sales position whereby Anna Malm Bernsten joins Aerocrine's management team from mid September with the responsibility for global sales.
Aug 24, 2007
AEROCRINE REINFORCES MANAGEMENT TEAM
SOLNA, Stockholm – 24th of August 2007 – In August Kjell Alving, Professor at the Karolinska Institute, joined Aerocrine’s management team responsible for scientific and medical affairs.
Jan 25, 2007
AEROCRINE APPOINTS NEW CEO
SOLNA, Sweden -- Jan. 25, 2007 -- Aerocrine today announced the appointment of Paul de Potocki to the position of President and Chief Executive Officer, Aerocrine AB, effective from February 1, 2007. Paul succeeds Thomas Almesjö who has led the development of Aerocrine since its foundation, and who is now moving on to assignments outside the company.
Sep 30, 2006
Swedish asthma-instrument launched into space: How much dust does an astronaut eat?
A novel instrument developed to help asthma patients is about to be launched to the International Space Station (ISS) in the frame of the European exploitation programme run by the European Space Agency (ESA). The instrument will be used to support scientific investigations on the effect of inhalation of dust particles and lung performances after space walks outside the station.
Mai 1, 2003
A first-of-a-kind, non-invasive test to monitor asthma - NIOX cleared by the FDA